Service profile
Nuvalent
Biopharmaceutical company developing brain-penetrant ROS1 and ALK inhibitors for treating non-small cell lung cancer and other solid tumors with kinase-driven mutations using structure-based drug design.
About
What Nuvalent is
Biopharmaceutical company developing brain-penetrant ROS1 and ALK inhibitors for treating non-small cell lung cancer and other solid tumors with kinase-driven mutations using structure-based drug design.
losclouds keeps public details for this profile. There are no catalog offerings to compare yet.
EnterpriseHealthcare
At a glance
| Fact | Value |
|---|---|
| Official site | https://nuvalent.com |
| Status coverage | Public status page |
| Founded | 2017 |
| Headquarters | Cambridge, Massachusetts, United States |
| Categories | Enterprise, Healthcare |
Loading offerings...